Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study

Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.

Authors

Institutions

Publication Details

Journal
Actas Dermo-Sifiliográficas
Published
2025-12-13
DOI
https://doi.org/10.1016/j.ad.2025.104562
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study

Manuel Almenara‐Blasco, Rafael S. Aguayo‐Ortiz, Emili Masferrer, E Vilarrasa-Rull et al.
Actas Dermo-Sifiliográficas
Hidradenitis Suppurativa and Treatments
article

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study

Manuel Almenara‐Blasco, Rafael S. Aguayo‐Ortiz, Emili Masferrer, E Vilarrasa-Rull, Pablo Fernández‐Crehuet, F. Alfageme-Roldán, Marta Gamissans, Marcelo Mansilla, Rosa Fornons‐Servent, O. Corral, M. Moya, J. Garcias‐Ladaria, J.M. Ortiz-Salvador, Julio Bassas‐Vila, Gemma Ochando‐Ibernón, Antonio Martorell, Laura Pericet‐Fernández, Adrián Imbernón, Verónica Mora‐Fernández, Sofía Haselgruber, Ferrán Navarro, I. Torres-Navarro, Rosa García-Ruiz, L. Carnero‐González, Aida Menéndez‐Parrón, P Garbayo-Salmons, I. Gracia-Darder, Pedro Gil Pallares, Alejandro Molina Leyva, I Fuertes-de-Vega, M Solera-Talamante, J Melgosa
article en

Abstract

Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.

Actas Dermo-SifiliográficasVol. 117(4)
Hospital de Sant Pau (ES), Bellvitge University Hospital (ES), Hospital Universitari i Politècnic La Fe (ES), University Hospital Mútua de Terrassa (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Universitario Príncipe de Asturias (ES), Hospital Universitario Araba (ES), Hospital Universitario Miguel Servet (ES), Hospital Clínic de Barcelona (ES), Corporació Sanitària Parc Taulí (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Arnau de Vilanova (ES), Hospital de Manises (ES), Hospital Universitario Reina Sofía (ES), Hospital Universitario Doctor Peset (ES), Hospital General Universitario De Valencia (ES), Hospital Universitario Lluís Alcanyís (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitario Severo Ochoa (ES)
Openalex Percentile: Top 37%
Hidradenitis Suppurativa and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.